Surgery and doxorubicin in dogs with hemangiosarcoma.

摘要: Forty-six dogs with histologically confirmed hemangiosarcoma of various locations other than skin were used in a prospective study to determine the efficacy adjuvant doxorubicin (30 mg/m2 IV q 3 weeks for 5 treatments) 10 14 days after tumor was partially or completely excised. Analysis data included information on variables that hypothesized influence response therapy, disease-free interval (DFI), survival time (ST). Other collected age, gender, breed, weight, prior type surgery, location primary tumor, presence metastases, number doses doxorubicin, therapy (complete partial response), and following histological criteria: overall differentiation, nuclear pleomorphism, percent necrosis, mitotic score, total grade. Surgery outcome versus incomplete surgical excision) markedly influenced times (P < .001). Twenty rendered free disease alive at 1 year, whereas none had residual surgery year. Most criteria (nuclear grade, differentiation) marked .05), close marked, independent associations ST complete removal. Results from analysis DFI generally similar those excision tumor. Twenty-seven 46 (58.7%) all clinical evidence tumour successfully removed. Logistic regression (ability remove visible tumor) suggested age subject only factor influencing = .017). As increased, probability success increased. Those previous treatment their tended .08) have shorter ST. Therefore, removal followed by may be an effective hemangiosarcoma. Dogs removed mean median 267 172 days, respectively. 60 Similarly, prognostic such as ability excise criteria, patient are potentially important predicting outcome.